NeuroOne Grants Equity Award to New Hire Under Inducement Plan

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced that its independent directors approved an equity award under the company's 2021 Inducement Plan as a material inducement for a new employee. The award, effective June 24, 2026, was granted in compliance with Nasdaq Listing Rule 5635(c)(4), which mandates public disclosure of equity awards not made under a stockholder-approved plan. The new hire, who was not previously an employee or director of NeuroOne, received an option to purchase 10,000 shares of common stock at an exercise price of $3.27 per share, the closing price on the grant date. The option has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder in 12 equal quarterly installments, contingent on continued employment.

NeuroOne markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.

This equity award is part of NeuroOne's strategy to attract key talent to drive its mission of transforming neurological care. The company's innovative electrode technology platform has the potential to revolutionize how neurological disorders are diagnosed and treated, offering hope for patients with conditions such as epilepsy and chronic pain. By incentivizing new hires with stock options, NeuroOne aligns employee interests with shareholder value, fostering long-term growth and innovation.